Thirty years is a long time in most of our lives -if not in publishing -and so it is right that we celebrate this anniversary for Journal of Psychopharmacology. Reflecting on the origins of the Journal, it was developed by its founding organisation, the British Association of Psychopharmacology (BAP), to provide a vehicle for spreading scientific discoveries in our discipline and also an alternative financial income stream for the Association. On both counts Journal of Psychopharmacology has succeeded. It has become one of the leading journals in our discipline with an impact factor that puts it in the top quartile of the Clinical Neurology, Psychiatry and Pharmacology & Pharmacy JCR disciplines and second quartile for Neurosciences. This is a remarkable success and one which emphasises the broad content that we encourage: ranging from preclinical research on receptor and behavioural pharmacology through to clinical trials, neuroimaging studies and even policy positions and consensus statements. Journal of Psychopharmacology also has rewarded the investment of the BAP by providing a significant and growing income stream that has helped the Association develop a financially secure infrastructure with its own offices and full-time staff.
The BAP committee and the Journal team of myself, my co-editor, Pierre Blier, and the managing editor, Pallab Seth, considered for some time the best way to celebrate Journal of Psychopharmacology's third decade. From a number of suggestions we decided that the best option would be to reprint some of the most cited papers that Journal of Psychopharmacology had ever published. To add value we would publish along with this a commentary by the original author(s) giving an update on the impact that their paper had made and emphasising the significance of the work to the emerging field. We approached the senior or lead authors of the top 15 most cited research papers ever, with the exception of Deakin and Graeff (1991) , whose classic '5-HT and mechanisms of defence' had been the lead in a special issue in 2013 (Deakin, 2013) .
We were delighted that 10 of those approached agreed to write commentaries and even more pleased when they came in on time for this issue! So here you see the results of this exercise: 10 excellent papers updated and in some cases expanded by the original authors. They cover a wide range of clinical and preclinical topics by leaders in their fields and also span the whole world with authors from the Americas, through Europe to the Antipodes.
I have had the pleasure of reading and (lightly) editing each, which was a particularly fun and educational thing to do. I would highly recommend that all of you read those commentaries most closely aligned to your own research interests and if you have time, read a few of the others to broaden your knowledge of this broad field of psychopharmacology. I think they justify our view that Journal of Psychopharmacology is a leading voice for the publication of the very highest quality research in psychopharmacology and as a collection they provide an impressive celebration of our journal's legacy over the past 30 years.
